Articles

If your business sells or advertises paracetamol, then you need to be aware of the new rules around pack sizes that commence on 1 February 2025.

This instrument is made under section 39 of the current Poisons Standard.

This instrument is made under section 39 of the current Poisons Standard.

We are providing a 12-month period of labelling exemptions for signal words for certain Pharmacy medicine and Pharmacist Only medicine products.

This instrument is the Therapeutic Goods (Poisons Standard) (Benzylpenicillin—Seqirus) Approval 2024.

Find out about changes to choline salicylate access, starting from October 2023.

Stay updated about the commencement of MDMA and psilocybin for the treatment of certain mental illnesses.

The TGA has published a final decision to reduce the maximum size of packs for various paracetamol products.

From 1 June 2023, prescribing of oral ivermectin for ‘off-label’ uses will no longer be limited to specialists such as dermatologists, gastroenterologists and infectious diseases specialists.

From 1 July 2023, authorised psychiatrists can prescribe psychedelic medicines to people with specific mental health conditions under strict controls.

The TGA has today published an interim decision to reduce the maximum pack sizes for various paracetamol products.

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

The TGA has published an independent expert report examining the incidence of serious injury and death from intentional paracetamol overdose.

This labelling exemption is granted under section 1.1(3) of Part 2 of the current Poisons Standard.

Today the TGA announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations

No lasting increase in consumption following up-scheduling of low-dose products